



## **CytoTools AG strengthens successful subsidiary DermaTools Biotech GmbH with further capital increase**

- DermaTools receives fresh capital of EUR 2.3 million
- CytoTools AG and an existing shareholder subscribe new shares
- Means will be used to extend research activities on the active substance DermaPro® as well as for repayment of all the company's liabilities
- CytoTools AG intensifies exploration of strategic options

Darmstadt, 28<sup>th</sup> April 2014 – A capital increase to EUR 132,000 in share capital was agreed unanimously on 16<sup>th</sup> April 2014 at the partners' meeting of DermaTools Biotech GmbH, a subsidiary of CytoTools AG. Within the scope of this capital increase, the CytoTools AG and an existing shareholder have made available new capital with a total of EUR 2.3 million. With this, among other things, all the liabilities of DermaTools can be removed so that now the company is free of foreign capital. Within the scope of its financial possibilities the CytoTools AG is participating here and is thus keeping its share in DermaTools Biotech GmbH almost constant. Through this liquidity strengthening the CytoTools AG is supporting the successful research and development work of its subsidiary. Additionally, the complete repayment of all liabilities means that further opportunities for new strategic options can be explored.

The newly acquired financing is intended to be used for extending the clinical research into the active substance DermaPro® for other indication fields – beyond the area of dermatology – yielding further great potential for the innovative active substance molecule. Dr. Dirk Kaiser, joint managing director of the CytoTools AG, commented here: „Trials have shown that our own development is also effective for other indications.“ Thus DermaTools can extend its development work with its patented active substance molecule to further new indications.

„As well as the increased possibilities in the research and development fields, we consider it to be a great success that this capitalization round has put DermaTools in a position to repay all foreign capital. Thus, on the one hand, the high interest obligations are no longer due, and on the other hand, and this is more important, an excellent starting basis is created with which we can explore further strategic options“, concluded Dr. Mark-Andre Freyberg, joint managing director of the CytoTools AG.

## **PRESSE RELEASE**



# CytoTools

*This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 57% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

Press contact:

cometis AG

Ulrich Wiehle

Unter den Eichen 7

D-65195 Wiesbaden

Tel.: +49-611-205855-11

Fax: +49-611-205855-66

E-Mail: [wiehle@cometis.de](mailto:wiehle@cometis.de)